These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19303573)

  • 21. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function.
    Hsia J; Jablonski KA; Rice MM; Sabatine MS; Zabalgoitia M; Maggioni A; Cuddy TE; Domanski MJ; Geller NL; Flaker G; Solomon S; Omland T; Rouleau JL;
    Am J Cardiol; 2008 Feb; 101(4):457-61. PubMed ID: 18312757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Towards the optimal management in 2004 of patients with stable coronary artery disease].
    Solignac M
    Presse Med; 2004 Sep; 33(16):1074-6. PubMed ID: 15523259
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
    Syvänne M
    Duodecim; 1999; 115(10):1167-73. PubMed ID: 11877856
    [No Abstract]   [Full Text] [Related]  

  • 25. [Remodeling with angiotensin-converting enzyme inhibitors: from GISSI to PREAMI].
    Nicolosi GL
    Ital Heart J; 2005 Nov; 6 Suppl 7():33S-39S. PubMed ID: 16485515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
    Baer JT; Sauer WH; Berlin JA; Kimmel SE
    Am J Cardiol; 2004 Aug; 94(4):479-81. PubMed ID: 15325933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.
    Battes L; Barendse R; Steyerberg EW; Simoons ML; Deckers JW; Nieboer D; Bertrand M; Ferrari R; Remme WJ; Fox K; Takkenberg JJ; Boersma E; Kardys I
    Am J Cardiol; 2013 Jul; 112(1):27-33. PubMed ID: 23558041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perindopril protects diabetics with coronary disease from cardiovascular death and heart attacks.
    Cardiovasc J S Afr; 2004; 15(2):98. PubMed ID: 15148549
    [No Abstract]   [Full Text] [Related]  

  • 29. Painful legs, aching heart: Reducing cardiovascular risk in patients with peripheral arterial disease with angiotensin-converting enzyme inhibition.
    Gupta MK; Verma S
    Can J Cardiol; 2005 Feb; 21(2):194-5. PubMed ID: 15729422
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary prevention of myocardial infarction: putting the evidence to use.
    Herzog E; Javed F
    Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965
    [No Abstract]   [Full Text] [Related]  

  • 31. PRO: Preoperative coronary revascularization in high-risk patients undergoing vascular surgery.
    Landesberg G; Mosseri M
    Anesth Analg; 2008 Mar; 106(3):759-63. PubMed ID: 18292414
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
    Al-Omran M; Lindsay TF
    Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic strategies in patients with chronic stable coronary artery disease.
    Zellweger MJ; Pfisterer ME
    Cardiovasc Ther; 2011 Dec; 29(6):e23-30. PubMed ID: 20491783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.
    Brugts JJ; Danser AH; de Maat MP; den Uil CA; Boersma E; Ferrari R; Simoons ML
    Curr Opin Cardiol; 2008 Jul; 23(4):296-301. PubMed ID: 18520711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. It's not the dye, but the "die" in dialysis: which coronary revascularization strategy really is best?
    Butman SM
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):949-50. PubMed ID: 21108371
    [No Abstract]   [Full Text] [Related]  

  • 37. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
    White HD
    Lancet; 2003 Sep; 362(9386):755-7. PubMed ID: 13678865
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
    Lazar HL
    Vascul Pharmacol; 2005 Feb; 42(3):119-23. PubMed ID: 15792929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.